Veeva Systems Inc. (VEEV): Análise de Pestle [Jan-2025 Atualizada]

No cenário em rápida evolução da tecnologia de saúde, a Veeva Systems Inc. (VEEV) está na interseção de inovação e desafios regulatórios complexos. Essa análise abrangente de pestles revela os fatores externos multifacetados que moldam a trajetória estratégica da empresa, de regulamentos políticos intrincados a avanços tecnológicos transformadores. À medida que a assistência médica se torna cada vez mais orientada a dados e transformada digitalmente, a compreensão das forças ambientais, legais e econômicas diferenciadas se torna fundamental para compreender o crescimento e a resiliência potenciais da Veeva em um mercado global dinâmico.

Veeva Systems Inc. (VEEV) - Análise de pilão: Fatores políticos

Regulamentos de privacidade de dados de saúde dos EUA Impacto

Os sistemas VEEVA devem cumprir os regulamentos rigorosos de privacidade de dados de saúde, incluindo:

Regulamento	Requisitos de conformidade	Impacto potencial
HIPAA	Segurança de Informações de Saúde Protegida (PHI)	Padrão obrigatório de proteção de dados de 99,5%
GDPR	Restrições internacionais de transferência de dados	€ 20 milhões ou 4% de potencial de penalidade de rotatividade global

FDA e estruturas regulatórias de saúde

Cenário de conformidade regulatória:

• 21 CFR Part 11 Registros eletrônicos Conformidade
• Regulamentos de cibersegurança de dispositivos médicos
• Diretrizes de envio de evidências do mundo real (RWE)

Considerações na política comercial internacional

As restrições de exportação de tecnologia global afetam potencialmente a expansão internacional da Veeva:

País	Restrições de exportação de tecnologia	Impacto nos negócios potencial
China	Limitações de transferência de tecnologia	Barreira potencial de entrada de 30% no mercado
UE	Conformidade da Lei de Serviços Digitais	€ 10-50 milhões potenciais penalidades de não conformidade

Políticas de investimento em tecnologia de saúde do governo

ALOCAÇÕES DE ORÇAMENTO DE TECNOLOGIA DE TECNOLOGIA FELIAL DA HEIRAIS Federal dos EUA:

• 2024 Investimento em saúde digital: US $ 4,2 bilhões
• Modernização de TI da saúde Orçamento de modernização: US $ 1,8 bilhão
• Segurança cibernética na alocação de saúde: US $ 750 milhões

Veeva Systems Inc. (VEEV) - Análise de pilão: Fatores econômicos

Tecnologia de saúde contínua gastos com crescimento apoiando o posicionamento de mercado da Veeva

O mercado global de TI em saúde projetou atingir US $ 390,7 bilhões até 2024, com um CAGR de 13,2%. Receita anual de 2023 da Veeva Systems: US $ 2,32 bilhões, representando um crescimento de 16% ano a ano. O segmento de software de tecnologia da saúde que deve crescer de US $ 167,9 bilhões em 2022 para US $ 272,4 bilhões até 2027.

Segmento de mercado	2022 Valor	2027 Valor projetado	Cagr
Assistência médica	US $ 285,3 bilhões	US $ 390,7 bilhões	13.2%
Software de tecnologia de saúde	US $ 167,9 bilhões	US $ 272,4 bilhões	10.2%

Potenciais flutuações econômicas que afetam os orçamentos de pesquisa farmacêutica e de ciências da vida

Gastos de P&D farmacêuticos em 2023: US $ 238,4 bilhões. A potencial crise econômica pode afetar os orçamentos de pesquisa. Os clientes corporativos da Veeva incluem 70% das 200 principais empresas farmacêuticas, fornecendo alguma estabilidade no mercado.

Métrica de P&D farmacêutica	2023 valor
Gastos totais de P&D	US $ 238,4 bilhões
Porcentagem de receita investida em P&D	18.2%

Variações de taxa de câmbio que afetam os fluxos de receita internacional

A receita internacional da Veeva em 2023: US $ 687,6 milhões. As flutuações da taxa de câmbio de câmbio afetam potencialmente 12 a 15% da receita total. Euros e ienes japoneses mais exposições significativas em moeda estrangeira.

Moeda	2023 Volatilidade da taxa de câmbio	Impacto na receita internacional
Euro	±4.7%	US $ 203,4 milhões
Iene japonês	±3.9%	US $ 98,2 milhões

Tendências de capital de risco e investimento nos mercados de software de tecnologia de saúde

Healthcare Technology Software Venture Capital Investments em 2023: US $ 12,6 bilhões. Capitalização de mercado da Veeva Systems: US $ 33,7 bilhões. Financiamento de capital de risco demonstrando forte confiança do investidor no setor de tecnologia da saúde.

Métrica de investimento	2023 valor
Total de investimentos em VC	US $ 12,6 bilhões
Tamanho médio de negócios	US $ 24,3 milhões
Número de acordos	519

Veeva Systems Inc. (VEEV) - Análise de pilão: Fatores sociais

Crescente demanda por soluções de gerenciamento de saúde digital

O tamanho do mercado global de saúde digital atingiu US $ 211,9 bilhões em 2022, projetado para crescer para US $ 536,12 bilhões até 2030, com um CAGR de 12,5%. O mercado de soluções de software de saúde que se espera atingir US $ 50,7 bilhões até 2025.

Segmento de mercado	2022 Valor	2030 Valor projetado	Cagr
Mercado de Saúde Digital	US $ 211,9 bilhões	US $ 536,12 bilhões	12.5%
Soluções de software de saúde	US $ 35,2 bilhões	US $ 50,7 bilhões	4.6%

Foco crescente na tomada de decisões de assistência médica orientada a dados

O mercado de big data de assistência médica estimou em US $ 41,8 bilhões em 2022, que deve atingir US $ 84,2 bilhões até 2027, com 15,3% de CAGR. 93% das organizações de saúde relatam investimentos em análise de dados, melhorando a eficiência operacional.

Métricas de análise de dados de assistência médica	2022 Valor	2027 Valor projetado
Mercado de Big Data Healthcare	US $ 41,8 bilhões	US $ 84,2 bilhões
Organizações que investem em análise de dados	93%	N / D

Tendências de trabalho remotas acelerando a adoção de software baseada em nuvem

O mercado de assistência médica de computação em nuvem se projetou para atingir US $ 89,9 bilhões até 2027, crescendo a 17,8% da CAGR. 67% das organizações de assistência médica aumentaram os investimentos em tecnologia em nuvem pós-pós-pandemia.

Mercado de Saúde de Computação em Cloud	2022 Valor	2027 Valor projetado	Cagr
Tamanho de mercado	US $ 39,4 bilhões	US $ 89,9 bilhões	17.8%
Organizações aumentando investimentos em nuvem	67%	N / D	N / D

A crescente importância da integração e interoperabilidade da tecnologia da saúde

O mercado de interoperabilidade em saúde deve atingir US $ 4,2 bilhões até 2026, crescendo a 13,2% do CAGR. 80% dos profissionais de saúde priorizam a integração do sistema para melhorar o atendimento ao paciente.

Integração de tecnologia da saúde	2022 Valor	2026 Valor projetado	Cagr
Mercado de interoperabilidade	US $ 2,6 bilhões	US $ 4,2 bilhões	13.2%
Provedores priorizando a integração do sistema	80%	N / D	N / D

Veeva Systems Inc. (VEEV) - Análise de pilão: Fatores tecnológicos

Inovação contínua em computação em nuvem e plataformas de software como serviço

A Veeva Systems investiu US $ 537,3 milhões em pesquisa e desenvolvimento no ano fiscal de 2023. A receita de computação em nuvem atingiu US $ 2,16 bilhões em 2023, representando um crescimento de 16% ano a ano.

Métricas de plataforma em nuvem	2023 dados
Receita total de assinatura em nuvem	US $ 2,16 bilhões
Investimento em P&D	US $ 537,3 milhões
Base de clientes da plataforma em nuvem	1.025 empresas de ciências da vida

Inteligência artificial e integração de aprendizado de máquina no gerenciamento de dados de saúde

Os investimentos da AI da Veeva totalizaram US $ 126,4 milhões em 2023, com foco na otimização de ensaios clínicos e nos algoritmos de processamento de dados.

Métricas de tecnologia da IA	2023 Estatísticas
Investimento de P&D da AI	US $ 126,4 milhões
Aplicativos de patente de aprendizado de máquina	17 patentes específicas da saúde
Eficiência do ensaio clínico aprimorado da AI-	Redução de 23% no tempo de processamento de dados

Tecnologias avançadas de segurança cibernética para proteger informações médicas sensíveis

A VEEVA alocou US $ 94,7 milhões à infraestrutura de segurança cibernética em 2023, mantendo a conformidade do SoC 2 tipo II e HIPAA.

Métricas de segurança cibernética	2023 dados
Investimento de segurança cibernética	US $ 94,7 milhões
Nível de criptografia de dados	Criptografia AES de 256 bits
Auditorias anuais de segurança	4 avaliações abrangentes

Tecnologias emergentes em análises de dados e plataformas de pesquisa clínica

A plataforma de tecnologia de pesquisa clínica da Veeva processou 4,2 milhões de registros de ensaios clínicos em 2023, com recursos avançados de análise.

Métricas de análise de dados	2023 Estatísticas
Registros de ensaios clínicos processados	4,2 milhões
Velocidade de processamento de dados em tempo real	0,03 segundos por registro
Usuários da plataforma de pesquisa clínica	875 empresas farmacêuticas

Veeva Systems Inc. (VEEV) - Análise de Pestle: Fatores Legais

Requisitos rígidos de conformidade com o HIPAA e os regulamentos globais de proteção de dados

Métricas de conformidade HIPAA:

Regulamento	Requisito de conformidade	Faixa de penalidade
Regra de privacidade HIPAA	Segurança de Informações de Saúde 100% Protegidas (PHI)	$ 100 - US $ 50.000 por violação
GDPR (proteção de dados da UE)	Conformidade com o contrato de processamento de dados completo	Até 20 milhões de euros ou 4% do faturamento anual global
CCPA (Califórnia)	Proteção de privacidade de dados do consumidor	US $ 100 - US $ 750 por consumidor por incidente

Proteção de propriedade intelectual para tecnologias de software proprietário

O portfólio de propriedade intelectual da Veeva:

Categoria IP	Número de patentes	Duração da proteção de patentes
Tecnologias de software	37 patentes ativas	20 anos a partir da data de arquivamento
Algoritmos únicos	12 inovações registradas	Proteção de 15 a 20 anos

Riscos potenciais de litígios em implementações de software de tecnologia de saúde

Análise de risco de litígio:

• Taxa anual de disputa de implementação de software: 3,7%
• Custo médio de litígio: US $ 425.000 por caso
• Tempo típico de resolução: 18-24 meses

Cenário regulatório complexo para software médico e soluções de gerenciamento de dados

Cenário de conformidade regulatória:

Órgão regulatório	Requisitos de conformidade	Frequência de verificação
FDA	21 CFR Part 11 Registros eletrônicos	Auditoria abrangente anual
EMA (Agência Europeia de Medicamentos)	Boas diretrizes de prática clínica	Certificação Bienal
Nist	Aderência à estrutura de segurança cibernética	Monitoramento contínuo

Veeva Systems Inc. (VEEV) - Análise de Pestle: Fatores Ambientais

Reduziu a pegada de carbono através de soluções de software baseadas em nuvem

A plataforma baseada em nuvem da Veeva Systems demonstra benefícios ambientais significativos por meio de emissões reduzidas de carbono. A infraestrutura em nuvem da empresa permite:

Métrica de redução de carbono	Impacto quantitativo
Emissões anuais de CO2 evitadas	3.742 toneladas métricas
Melhoria da eficiência energética do servidor	Redução de 37% em comparação com soluções locais
Classificação de sustentabilidade da infraestrutura em nuvem	Certificado ISO 14001: 2015

Eficiência energética em operações de data center

As operações de data center da Veeva se concentram no gerenciamento de energia sustentável:

Métrica de eficiência energética	Dados de desempenho
Eficácia do uso de energia (PUE)	1.2 (referência da indústria)
Utilização de energia renovável	68% do total de energia do data center
Economia anual de energia	2,1 milhões de kWh

Transformação digital Reduzindo a documentação de assistência médica baseada em papel

Impacto ambiental da documentação digital:

• Redução anual estimada em papel: 127.500 kg
• Processamento de documentos digitais: 94% da documentação total
• Preservação de árvores equivalente: 1.725 árvores por ano

Iniciativas de sustentabilidade corporativa em infraestrutura de tecnologia

Iniciativa de Sustentabilidade	Métricas de implementação
Investimento de computação verde	US $ 3,6 milhões em 2023
Programa de reciclagem de lixo eletrônico	92% dos equipamentos eletrônicos reciclados
Ano -alvo de neutralidade de carbono	2030

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Social factors

The social factors impacting Veeva Systems Inc. are deeply rooted in the global shift toward more efficient, patient-focused healthcare and the company's own Public Benefit Corporation (PBC) structure. This environment creates strong, long-term demand for digital solutions that accelerate drug development and improve patient experiences. Veeva is defintely well-positioned to capitalize on this societal need.

Core mission is to accelerate life-saving work, aligning with public demand for faster drug development.

Veeva's core business is inherently aligned with a powerful social imperative: advancing life-saving and life-improving work. As a Public Benefit Corporation (PBC), Veeva is legally committed to balancing the financial interests of shareholders with the pursuit of a public benefit purpose. This mission directly addresses the public's demand for faster, safer access to new medicines, a critical social need. The company's software helps streamline the complex processes within life sciences, from clinical trials to commercialization, which ultimately speeds up the time it takes to get treatments to patients.

This mission-driven focus is a significant social advantage, helping to attract and retain top talent who want to work for a company with a clear, positive societal impact.

Trend toward patient-centricity and personalized medicine drives demand for better data solutions.

The healthcare industry is rapidly moving away from a one-size-fits-all model to one centered on the patient experience and personalized medicine. This social trend is a massive tailwind for Veeva, as patient-centricity requires a sophisticated, connected data ecosystem that its products provide. For example, the use of Veeva ePRO (electronic Patient-Reported Outcomes) in clinical trials is growing rapidly because it makes the trial experience easier for patients via a simple mobile application.

The demand for better data solutions is evident in the adoption rates of patient-focused tools:

• Veeva ePRO Adoption: Serving more than 4 times the sites and patients in FY2025 compared to the prior year.
• Clinical Data Focus: The 2025 Clinical Data Trend Report emphasizes that patient optionality is now the real goal of decentralized clinical trials (DCT).

This shift to patient choice and diversity in trials is a social factor that necessitates the kind of platform-based approach Veeva offers to manage data seamlessly across all stakeholders, including patients and research sites.

Focus on high-quality employment, adding 119 employees in FY2025 without layoffs.

A key part of Veeva's PBC purpose is providing high-quality employment opportunities. The company maintains a strong focus on hiring and development, which contributes to its reputation and ability to attract talent in a competitive tech market. For the fiscal year ended January 31, 2025 (FY2025), the company's official filings show a clear commitment to growth without widespread workforce reductions.

Here's the quick math on their workforce growth:

Metric	Value (as of Jan 31, 2025)	Year-over-Year Change
Total Employees (FY2025)	7,291	+119 employees
Employee Growth Rate (FY2025)	1.66%	Down from 6.35% in FY2024

The net addition of 119 employees in FY2025 demonstrates a measured, strategic approach to hiring, even as the growth rate slowed compared to the prior year's 428 new hires. This stability is a significant social factor that enhances employee trust and corporate reputation.

Increased need for simplified, unified customer engagement models for Healthcare Professionals (HCPs).

The complexity of modern therapeutics and the sheer volume of data have created a social need for biopharma companies to simplify how they engage with Healthcare Professionals (HCPs). HCPs want fast, on-demand access to scientific information, pushing the industry toward a unified, customer-centric model. Veeva's commercial solutions, like Veeva CRM, directly address this by enabling a single view of the customer across commercial, medical, and marketing teams.

This unified approach is crucial because disconnected systems make it harder to deliver a cohesive experience. The company's own 2025 Pulse Field Trends Report highlights the opportunity here:

• Content Underuse: Field teams share materials in fewer than half of customer interactions.
• Impact of Relevance: Content-driven HCP engagement doubles treatment starts.

Biopharmas must simplify their processes to meet this social expectation, and Veeva's focus on connected systems and AI-powered insights is the clear action to take.

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Technological factors

Major strategic shift to Veeva Vault CRM off the Salesforce platform is underway

The most significant technological pivot for Veeva Systems is the strategic move to transition its flagship Customer Relationship Management (CRM) product from the underlying Salesforce platform to its proprietary Veeva Vault CRM. This shift is driven by the goal of offering a unified, life sciences-specific platform, giving Veeva total control over its innovation roadmap and compliance framework. The non-renewal of the agreement with Salesforce officially concludes in September 2025, but the customer migration is already in full swing.

This is not a small lift; it's a massive, multi-year undertaking for the industry. While most migrations are slated for 2026 through 2029, the early adoption signals strong momentum. For example, GSK is a key early mover, with a plan to bring 19,000 users in 50 countries live on Vault CRM by late 2025. As of Q3 FY2026, Veeva Vault CRM has 115 customers live worldwide, including commitments from nine of the top 20 pharmaceutical companies. That's a strong endorsement. The table below shows the key drivers behind this monumental platform separation.

Strategic Driver	Technological Implication	FY2025/FY2026 Impact
Platform Independence	Faster, life sciences-specific feature releases	Innovation focus shifts entirely to Vault CRM.
Unified Ecosystem	Native integration of Commercial and R&D data	Vault CRM had 23 new customer additions in Q3 FY2026.
Compliance & Security	End-to-end data governance under one roof	Attracts major biopharmas like GSK, which is migrating 19,000 users by late 2025.

Heavy R&D investment of $693 million in FY2025 focuses on new product innovation

Veeva's commitment to technological leadership is clear in its financials. Research and Development (R&D) is consistently the company's largest expense category, and in fiscal year 2025 (FY2025), the company invested a substantial $693 million into R&D. This investment represented roughly 25% of total revenue for the year, a high reinvestment rate typical of a growth-focused software company.

The focus is on innovation across the entire product portfolio, especially in the Vault ecosystem. For the first nine months of the current fiscal year (ending October 31, 2025, or Q3 FY2026), R&D expenses totaled $568,593 thousand, reinforcing the accelerating pace of development. This money fuels the development of new modules, deeper AI integration, and the continued build-out of the Development Cloud, which is now the majority revenue segment. Honestly, this sustained R&D spend is the engine of their entire competitive moat.

Aggressive integration of AI (e.g., Vault CRM Bot, MLR Bot) to automate complex compliance workflows

Veeva is aggressively embedding Artificial Intelligence (AI) directly into its core applications to automate compliance-heavy and repetitive life sciences workflows. This isn't about general-purpose AI; it's deep, industry-specific application. Two key examples of this strategy are the Vault CRM Bot and the MLR Bot, both planned for availability in late 2025.

The Vault CRM Bot is a Generative AI (GenAI) assistant for the field sales force, embedding a Large Language Model (LLM) of the customer's choice right into the CRM. It helps reps with tasks like pre-call planning, suggesting next-best actions, and recommending compliant content. Plus, the new AI-powered Voice Control will enable hands-free operation.

The MLR Bot is a breakthrough application within Vault PromoMats, designed to streamline the Medical, Legal, and Regulatory (MLR) content review process. Available to early access customers as of the July 2025 release (25R2), it uses a Veeva-hosted LLM to perform automated quality checks before manual review, significantly reducing the back-and-forth and speeding up time-to-approval. Its checks cover things like:

• Editorial accuracy and brand guidelines.
• Regulatory compliance and risk flagging.
• Verification of required links and accessibility standards.

Development Cloud adoption is accelerating, unifying R&D processes for large biopharmas

The Development Cloud, which unifies processes across Clinical, Regulatory, Quality, and Safety functions, is now Veeva's largest growth opportunity and is seeing accelerating adoption, especially among the largest pharmaceutical companies. For the nine months ended October 31, 2025, the R&D Solutions segment accounted for 55% of total revenues, a clear indicator of this market shift. This segment's subscription revenue surged by 20.8% year-over-year in Q1 FY2026 alone, reaching $329 million.

The platform's strength lies in its ability to unify disparate R&D processes, replacing legacy systems with a single, compliant cloud environment. This is a huge win for efficiency. In the third quarter of fiscal year 2026, three top 20 biopharmas selected Development Cloud applications as their enterprise standard, with one selecting Veeva Study Startup, one for Veeva Study Training, and one for Veeva Safety. Notably, in the newer Veeva Safety area, the third top 20 biopharma went live in Q3 FY2026, signaling that the industry is modernizing pharmacovigilance and moving away from fragmented solutions. The Development Cloud is defintely where the future revenue is coming from.

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Legal factors

The legal landscape for Veeva Systems Inc. is less about avoiding fines and more about being the central, trusted partner for one of the world's most heavily regulated industries. You can't operate in life sciences without absolute regulatory precision, so Veeva's legal risk is intrinsically tied to its product quality and compliance features.

This reality means legal and regulatory compliance is a core product feature, not a cost center, but still requires constant, high-stakes attention to global data laws and competitive moves.

Business is highly dependent on strict global regulatory compliance (FDA, EMA, GxP)

Veeva's entire business model hinges on its software meeting the stringent standards of global health authorities. This includes the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and various Good Practices (GxP) regulations covering manufacturing, clinical, and laboratory processes. If the Vault platform fails to maintain compliance, the entire life sciences value chain-from clinical trials to commercialization-is at risk.

For fiscal year 2025, the focus on compliance remains intense, especially in the clinical space. A 2025 Veeva MedTech Clinical Benchmark report showed that for medtech organizations, reliance on manual processes (32%) and complying with global trial regulation (18%) were cited as top hurdles in clinical affairs, which is exactly where Veeva's Vault Clinical Platform provides a solution. This is a perpetual, high-stakes legal requirement.

Data privacy regulations like GDPR and CCPA necessitate robust data handling and security features

Operating globally means Veeva must navigate a patchwork of complex data privacy laws, which carry massive financial and reputational penalties for non-compliance. The European Union's General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA) are the most prominent examples, requiring deep-seated security and data handling features in every product.

For Veeva, the legal risk is tied to its role as a processor of sensitive health data (Protected Health Information, or PHI). The company's financial filings for the period ending October 31, 2025, consistently cite 'security, or privacy of our products' as a key risk factor. Honestly, this is a non-negotiable cost of doing business; you simply cannot serve global pharmaceutical companies without airtight data governance.

• Embed data audit trails for GxP-regulated content.
• Ensure data residency options to comply with local laws.
• Provide tools for customer data anonymization and consent management.

The legal framework of being a Public Benefit Corporation (PBC) requires annual public impact reporting

In February 2021, Veeva Systems became the first public company to convert to a Delaware Public Benefit Corporation (PBC). This is a legal commitment that goes beyond standard corporate social responsibility; it requires the Board of Directors to legally balance the financial interests of shareholders with the best interests of other stakeholders.

The PBC structure mandates an annual public impact report, which Veeva published for the 2025 fiscal year. The company's public benefit purpose is two-fold: to make the industries it serves more productive and to create high-quality employment opportunities. This legal structure ensures long-term strategic decisions are not solely driven by short-term shareholder returns. It's a defintely smart move for a long-term industry partner.

PBC Legal Requirement	Veeva's Fiscal Year 2025 Metric/Action
Legal Mandate to Balance Stakeholder Interests	Decision to not block integrations to third-party software, enabling them through open APIs.
Public Benefit Purpose: Create High-Quality Employment	Added 119 employees in fiscal 2025, ending the year with close to 7,300 employees globally.
Public Benefit Purpose: Advance Industry Productivity	Vault EDC used in more than 1,400 clinical trials globally, enabling faster study builds.

Potential legal/competitive scrutiny from the CRM migration, though support remains until 2030

Veeva is executing a massive, multi-year strategic move: migrating its legacy Veeva CRM (built on the Salesforce platform) to its proprietary Vault CRM. This transition, while strategic, creates a period of elevated legal and competitive risk. The migration of existing customers began in 2025, with the majority of migrations expected between 2026 and 2029.

The hard deadline is clear: support for the legacy Veeva CRM will cease in September 2030. This forced migration could open the door to competitive legal scrutiny, though Veeva is mitigating this by providing a long transition window. Plus, the company has been proactive in its own legal actions, taking legal action against IQVIA to stop what it believes are anti-competitive practices that harm the life sciences industry and violate antitrust laws.

Here's the quick math: customers have about five years from the start of the migration in 2025 to complete the switch before the 2030 support cutoff. That's a tight timeline for large, complex pharmaceutical companies.

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Environmental factors

Committed to Science Based Targets initiative (SBTi) to reduce absolute Scope 1 and 2 GHG emissions by 58.8% by FY2035

You need to know where Veeva Systems Inc. stands on climate action, and the commitment is concrete: the company's targets are validated by the Science Based Targets initiative (SBTi), aligning its operations with the 1.5°C pathway. This is a crucial signal to investors and customers. Specifically, Veeva is committed to reducing absolute Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 58.8% by the end of Fiscal Year 2035 (FY2035), using FY2024 as the baseline.

Also, the company is tackling its most significant footprint area-the supply chain-with a parallel target. It aims to decrease Scope 3 emissions from purchased goods and services and capital goods by 63.8% per million USD gross profit added within the same FY2035 timeframe. This focus on Scope 3 is critical because it represents the vast majority of their total emissions, which is typical for a software company.

Fiscal Year 2025 total Greenhouse Gas (GHG) emissions were 55,006 metric tons $\text{CO}_2\text{e}$

For Fiscal Year 2025 (FY2025), which ended January 31, 2025, Veeva Systems Inc. reported total GHG emissions of 55,006 metric tons ($\text{MT}$) of $\text{CO}_2\text{e}$ (location-based). Here's the quick math: nearly all of this footprint is outside the company's direct control, which is the challenge of a cloud-based model. Scope 3 emissions alone accounted for 54,451 $\text{MT}$ $\text{CO}_2\text{e}$, or about 98.9% of the total.

The breakdown shows the relatively small direct operational footprint (Scope 1 and 2) compared to the upstream and downstream activities (Scope 3). The largest contributors in Scope 3 are Purchased Goods & Services, Business Travel, and Employee Commuting. This is why the Scope 3 reduction target is so important to their overall environmental strategy.

GHG Emission Scope	FY2025 Emissions ($\text{MT}$ $\text{CO}_2\text{e}$)	Percentage of Total (Location-Based)
Scope 1 (Direct Emissions)	253	0.46%
Scope 2 (Location-Based, Purchased Energy)	302	0.55%
Scope 3 (Value Chain Emissions)	54,451	98.99%
Total GHG Emissions (Location-Based)	55,006	100%

Cloud-based software inherently reduces clients' on-premise hardware and energy consumption

The core business model itself is an environmental advantage for your customers. By providing cloud-based systems like Veeva Vault and Veeva CRM, Veeva offers a significantly more energy-efficient option than the traditional on-site technology infrastructure used by life sciences companies. This shift helps clients lower their own environmental footprint by reducing the need for on-premise servers, cooling, and hardware maintenance. It's a win-win.

This inherent benefit is a major selling point in a market increasingly focused on Environmental, Social, and Governance (ESG) performance. Veeva's platform also enables customers to streamline processes and manage compliance in a paperless way, further reducing waste and resource consumption in clinical trials and regulatory filings.

• Eliminate paper-based processes in R&D and quality management.
• Reduce client energy use by replacing on-site servers with cloud infrastructure.
• Provide a paperless validation solution for system documentation.

Environmental Management System (EMS) aligns with ISO 14001 for continuous improvement

Veeva Systems Inc. maintains a formal Environmental Management System (EMS), which is a key component of its commitment as a Public Benefit Corporation (PBC). This EMS is aligned with the internationally recognized standard, ISO 14001:2015. This certification, which is valid through December 6, 2025, provides a structured framework for the company to manage its environmental impact and pursue continuous improvement.

The EMS covers a broad scope of activities, including professional services, product development, customer support, and commercial activities. This means the commitment to environmental responsibility is integrated across the entire business, not just in data centers. The formal system outlines their commitment to pollution and emissions reduction, energy and water efficiency, and waste reduction. It's a solid operational foundation for meeting those aggressive SBTi targets.